NLRP3 inflammasome

Overview

The NLRP3 inflammasome is a multiprotein complex of the innate immune system, assembled around the sensor protein NOD-like receptor family pyrin domain containing 3 (NLRP3, also called cryopyrin). Together with the adaptor protein ASC and the effector protease caspase-1, it forms a cytosolic signaling platform that converts diverse danger signals into an inflammatory response. Its assembly conventionally requires two steps: a priming signal, typically delivered through Toll-like receptor 4 and NF-κB–dependent transcription, which raises NLRP3 and pro-interleukin-1β levels, and an activation signal that triggers oligomerization. Once assembled, the complex activates caspase-1, which cleaves pro-IL-1β and pro-IL-18 into the mature cytokines interleukin-1β and interleukin-18, and cleaves Gasdermin D to release a pore-forming fragment that drives pyroptotic cell death and cytokine release.

NLRP3 is unusual among innate immune sensors in responding to a broad and chemically unrelated set of stimuli rather than a single ligand, integrating cues such as reactive oxygen species, mitochondrial dysfunction and mitochondrial DNA release, lysosomal destabilization, potassium efflux, and crystalline or aggregated material including amyloid beta. This positions it at the center of sterile inflammation, and it has been implicated in type 2 diabetes and diabetic complications such as diabetic kidney disease and diabetic cognitive impairment, obesity and metabolic dysfunction–associated steatotic liver disease, neurodegenerative and neuroinflammatory conditions including Alzheimer's disease and Parkinson's disease, traumatic brain injury, postoperative cognitive dysfunction, osteoporosis, and fibrotic and ischemic tissue injury. Regulatory inputs studied alongside it include TXNIP, the antioxidant transcription factor NRF2, SIRT1 signaling, mitophagy, and cross-talk with the cGAS-STING pathway. Pharmacologically, NLRP3 is an actively pursued anti-inflammatory target: the selective small-molecule inhibitor MCC950 is a standard experimental tool, and polyphenols and other natural products such as quercetin and gallic acid, mesenchymal stem cell– and extracellular vesicle–based approaches, nanoparticle formulations, and non-pharmacological interventions including electroacupuncture have all been examined for their ability to suppress inflammasome activation.

Recent Publications Summary (latest 30 papers)

Recent studies continued to position the NLRP3 inflammasome as a central mediator of inflammatory injury across metabolic, neurologic, renal, and fibrotic disease models. In diabetic and metabolic settings, irbesartan reduced high-glucose-induced epithelial-mesenchymal transition in HK-2 cells by downregulating NLRP3, caspase-1, and NF-κB p65, with effects comparable to MCC950 42318962Jun. In diabetic cognitive impairment, Akkermansia muciniphila improved learning and memory, reduced neuronal loss, and restored synaptic markers while inhibiting hippocampal NLRP3 inflammasome activation 42300325Jun. Related metabolic inflammation studies also linked high-salt diet to activation of NLRP3 signaling in macrophages, and protocatechuic acid was reported to suppress microglial inflammation in obesity-related models through NF-κB inhibition, a pathway closely connected to inflammasome priming 42224300Jun.

Multiple neuroinflammation studies identified NLRP3 as a therapeutic node in brain injury and neurodegeneration. Oxytocin alleviated LPS-induced cognitive and memory deficits by blocking the TLR4/NLRP3/NF-κB signaling pathway and reducing inflammatory cytokines and microglial activation 42049099Apr. glutathione-conjugated gold nanoparticles suppressed Aβ-induced neuroinflammation and tauopathy in a 3D human neural stem cell model by inhibiting NF-κB and the NLRP3 inflammasome, with reduced NLRP3, ASC, caspase-1, IL-1β, and IL-18 41997281Apr. Sulforaphane also inhibited NLRP3 inflammasome activation in Parkinson’s disease models by promoting mitophagy, restoring the CBS-H2S axis, and lowering mitochondrial ROS 41797134Mar. In traumatic brain injury, aging was associated with a dominant NLRP3-positive microglial state, and perturbation of NLRP3 or ELF1 improved outcomes in mouse models 42294901Jun41926211Apr. Additional reports described NLRP3-linked neuroprotection with theranekron in LPS-induced neuroinflammation 42189344May, trans-anethole in AlCl3-induced memory impairment 42154340May, quercetin in postoperative cognitive dysfunction 42209865May, and engineered mesenchymal stem cell-derived extracellular vesicles in acute glaucoma-induced neuroinflammation 41997056Apr.

Outside the nervous system, NLRP3 modulation was also reported in inflammatory, fibrotic, and tissue-injury models. electroacupuncture at ST36 and SP6 improved acute gouty arthritis and reduced NLRP3, caspase-1, and IL-1β in joint tissue while modulating circadian-inflammatory signaling 41967209Apr. Bone marrow-derived mesenchymal stem cells attenuated radiation pneumonitis by inhibiting NF-κB/NLRP3 signaling and reducing IL-1β, IL-18, and TNF-α 42026634Apr. Danggui-Shaoyao-San ameliorated metabolic dysfunction-associated steatohepatitis by suppressing hepatic macrophage NLRP3 inflammasome activation 41905728Mar, and a brominated celastrol derivative reduced hepatic fibrosis by blocking stimulus-induced NLRP3 activation in hepatic stellate cells 41844113Mar. In sepsis, M1 macrophage-derived exosomes were reported to promote intestinal barrier dysfunction and pyroptosis through NLRP3 inflammasome activation 42008763Apr, while Xue-Jie-San alleviated Crohn’s disease by suppressing endothelial cell pyroptosis via the TLR4/NF-κB/NLRP3 pathway 41936260Apr. Additional studies linked NLRP3 inhibition to reduced neuropathic pain 41991084Apr41934900Apr, improved postoperative delirium with sleep disturbances 41865457Mar, and enhanced antitumor or nephroprotective effects when combined with cisplatin or ginsenoside Rg3 42169649May.

What Changes, What Holds

1. NLRP3 remains a broadly actionable inflammatory node across metabolic and renal injury models
REINFORCES Irbesartan, Akkermansia muciniphila, and related metabolic interventions continue to fit the established view of NLRP3 as a mediator of sterile inflammation in diabetes and related disorders, rather than adding a new role. The main takeaway is practical: suppressing NLRP3 still tracks with improved epithelial, cognitive, and macrophage inflammatory phenotypes, and the new work strengthens the case for NLRP3 as a shared downstream readout in metabolic disease 42318962Jun42300325Jun.

2. Brain-injury and neurodegeneration studies keep extending NLRP3-centered neuroinflammation, but do not overturn the mechanism
REINFORCES Oxytocin, glutathione-conjugated gold nanoparticles, sulforaphane, and other interventions all support the existing account that NLRP3 participates in microglial activation, cytokine release, and neurotoxic injury in the brain. The added value is not a new biology but a broader therapeutic map, including mitophagy-linked suppression in Parkinson’s models and age-associated NLRP3-positive microglial states after traumatic brain injury 42049099Apr41797134Mar.

3. NLRP3 inhibition is being validated across more inflammatory tissues, but the baseline mechanism still stands
REINFORCES electroacupuncture, mesenchymal stem cells, herbal formulas, and exosome-based approaches all converge on the same inflammasome axis in gout, pneumonitis, steatohepatitis, fibrosis, sepsis, Crohn’s disease, pain, and delirium. That breadth reinforces the Overview’s view of NLRP3 as a central sterile-inflammation effector, while also showing that the recent literature is mostly expanding disease coverage and combination strategies rather than revising how the complex works 41967209Apr42026634Apr.